Clinical studies have demonstrated that the VERIGENE Bloodstream Infection assays lower overall hospital costs, shorten the patient's length of stay, and most importantly, improve patient outcomes by enabling a more targeted treatment plan—faster. 1 These assays have been proven to synergize with antimicrobial stewardship programs, reduce the use of unnecessary antibiotics, and effectively manage infection control. 1, Verigene®血液培養グラム陰性菌・薬剤耐性核酸テスト（BC-GN Verigene血液培養グラム陰性菌・薬剤耐性核酸テスト（BC-GN） 体外診断用医薬品 承認番号 22800EZX00025000 承認日 2016年4月26日 使用目的 血液培養陽性となった培養液中のグラム陰性菌の核酸同定及び薬剤耐性遺伝. The Verigene Gram-positive blood culture (BC-GP) and Gram-negative blood culture (BC-GN) nucleic acid tests (Nanosphere, Inc., Northbrook, IL) are microarray-based assays designed to rapidly identify multiple bacterial species and their associated resistance markers directly from positive blood cultures Verigene ® 血液培養グラム陰性菌・薬剤耐性核酸テスト (BC-GN
Intended use(s): The Verigene®Gram Negative Blood Culture Nucleic Acid Test (BC-GN), performed using the sample-to-result Verigene System, is a qualitative multiplexed in vitro diagnostic test for.. The Verigene BC-GN test is performed on positive blood culture bottles for the detection of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Acinetobacter spp., Citrobacter spp., Enterobacter spp., Proteus spp., and antibiotic resistance genes CTX-M, IMP, KPC, NDM, OXA, and VIM
Verigene BC-GN is an automated multiplex molecular diagnostic test that rapidly identifies genus, species and genetic resistance determinants for a broad panel of gram-negative bacteria directly from positive blood culture bottles The Verigene®Gram-Negative Blood Culture Nucleic Acid Test (BC-GN)performed using the sample-to- result Verigene®System, is a qualitative multiplexed in vitro diagnostic test for the simultaneous detection and identification of selected gram-negative bacteria and resistance markers The Verigene Gram-negative blood culture (BC-GN) assay (Nanosphere, Inc., Northfield, IL) is a FDA-approved, random-access, automated, multiplexed nucleic acid test for the rapid ID of the most common GNB (and selected resistance markers [RMs]) from blood cultures within 2 h of positivity (4)
NATtrol BC/GN is ready to use, inactivated full process controls designed to evaluate performance of molecular tests. They can be used for verification of assays, training of laboratory personnel and to monitor assay-kit lot performance Verigene血液培養グラム陰性菌・薬剤耐性核酸テスト（BC-GN 【VerigeneⓇシステムと敗血症パネル】 VerigeneⓇシステムは、検体装填後、核酸抽出からハイブリダイゼーションまでを自動で処理する遺伝子 検査システムで、VerigeneⓇプロセッサーと Verigeneリーダーから構成（図1上）されており、測定原理 にマイクロアレイ法（図2）を用いていることから、1回の測定で多種類の遺伝子を同時に検出します
General Information for the evaluation of the Verigene system with Verigene Gram-positive Blood Culture Test (BC-GP) and Verigene Gram-negative Blood Culture Test (BC-GN) for positive blood culture bottles Total N＝282 GP N＝104 GN N＝178 Incubation period for a positive signal obtained from blood culture bottle (h) 13.8 (11.8-18.4) 14.7 (11.8-20.3) 13.2 (11.9-18.2) Duration between the initiation of incubation and reporting of the Gram stain examination (h) 19.5 (16.2-24.5) 19.5 (16.5-26.6) 19.8 (16.0-24.4) Duration between the initiation of incubation and reporting of the Verigene system result (h) 22.7 (19.1-29.2) 22.5 (19.7-30.0) 22.9 (18.7-27.9) Number of target pathogens 282 104 178 One specie 262 98 164 Two species 10 3 7 Three species 0 0 0 Continuous data are presented as the median (interquartile range) ラトリーについては施設内に倫理審査委員会をもたな いため，研究計画書において倫理審査を筑波メディカ ルセンター病院に委託することを明記の上，同院での 倫理審査会の承認により実施した In contrast, the Verigene blood culture Gram-negative test (BC-GN) is an FDA-approved, automated microarray-based, multiplexed nucleic acid test for the rapid identification of the most common Gram-negative bacilli (Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Proteus spp., Citrobacter spp., Enterobacter spp., and Acinetobacter spp.) and detection of their drug resistance markers (KPC, NDM, CTX-M, VIM, IMP, and OXA) 2014年7月から2016年3月の期間で，血液培養陽性ボトル計262検体282株（BC-GP：101検体104株，BC-GN：171検体：178株）に対して解析した。血液培養開始よりVerigeneシステムの検査終了までの時間は中央値で22.7時間（ VERIGENE® Gram-Negative Blood Culture Nucleic Acid Test (BC-GN) (IVD) Peer-Reviewed Publications Impact of a Rapid Blood Culture Assay for Gram-Positive Identification and Detection of Resistance Markers in a Pediatric Hospital - Archives of Pathology & Laboratory Medicin The Verigene BC-GN was performed on all first positive GNR blood cultures. In addition, routine antibiotic susceptibility testing was performed on all isolates by the disk-diffusion method and included phenotypic ESBL testing usin
The performance of molecular tests using the Verigene Gram-Positive and Gram-Negative Blood Culture nucleic acid tests (BC-GP and BC-GN, resp.; Naosphere, Northbrook, IL, USA) was evaluated for the identification of microorganisms detected from blood cultures. Ninety-nine blood cultures containing Gram-positive bacteria and 150 containing Gram-negative bacteria were analyzed using the BC-GP. ・Verigene システムを用いたBC-GP 検査またはBC-GN 検査で検出された薬剤耐性遺伝子及び従来 法による薬剤感受性検査で検出された薬剤耐性の分布 （効果） 迅速な診断が行われることで、不要な抗菌薬の投与が減少し、最適 K122514 Verigene® Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) Summary Preparation Date: September 17, 2012 Submitted by: Nanosphere, Inc. 4088 Commercial Avenue Northbrook, IL 60062 Phone: 847-400. 表1 Verigene®BC-GP/GN テストカートリッジで検出可能な 病原体と耐性遺伝子 図2 POCT型の遺伝子検査システム A: GeneXpert Omni (Cepheid社) B: Cobas Liat (Roche社) C: Alere I (Alere社) 図3 MALDI-TOF MSを用いた微生物 16.
The Verigene Gram-positive blood culture test (BC-GP) and the Verigene Gram-negative blood culture test (BC-GN) identify representative Gram-positive bacteria, Gram-negative bacteria and their antimicrobial resistance by detecting resistance genes within 3 h. Significant benefits are anticipated due
2) Verigene® 血液培養グラム陰性菌・薬剤耐性核酸テスト（BC-GN）（株式会社日立ハイテクノロジーズ） 【測定対象】血液培養液からグラム陽性菌あるいはグラム陰性菌が確認された敗血症を疑う患 Improves Outcomes The VERIGENE® Bloodstream Infection portfolio empowers laboratories to rapidly identify causative pathogens, as well as their associated resistance markers. Clinical studies have demonstrated that the VERIGENE Bloodstream Infection assays lower overall hospital costs, shorten the patient's length of stay, and most importantly, improve patient outcomes by enabling a more.
Request PDF | An Antibiotic stewardship program (ASP) blueprint for optimizing Verigene BC-GN within an institution: A tale of two cities | Rapid diagnostic tests (RDTs) have revolutionized the. VERIGENE BC-GP and BC-GN Panels 遺伝子変異検出 ゲノム薬理学 xTAG CYP2D6 v3 IUO 薬物代謝関連遺伝子型判定キット(研究用) xTAG CYP2C19 v3 RUO 薬物代謝関連遺伝子型判定キット MultiCode® プライマー・試
SDS, Verigene BC-GN Utility Tray Kit, Greek (Greece) Downloads 23 Total Files 1 Create Date October 16, 2019 Last Updated April 12, 2020 Download [...]Read More.. Valutazione dei test Verigene ® BC-GP e Verigene ® BC-GN per l'identificazione molecolare rapida di agenti eziologici di sepsi e dei relativi determinanti genetici di antibiotico-resistenza a partire da flaconi di emocoltura positivi 1E.Rossetti, 1L.Collini, 1S.D'Arcangelo, 1C.Bezzi, 1P.Lanzafame, 1MB.Simione, 2F.Viganò, 3S.Cofan During the intervention period (N = 88), Verigene BC-GP and BC-GN was used along with conventional microbiological diagnostic methods, while comparing the clinical data and outcomes with those during the control period ( VERIGENE II System SYNCT Software VERIGENE II Flex Testing Credits xPONENT Software Our Technology xMAP Technology xTAG Technology MultiCode-RTx Technology VERIGENE NanoGrid Technology MagPlex-TAG. グラム陰性桿菌菌血症に対するVerigene システム BC-GNパネルを用いた耐性遺伝子検出による第3世代セフェム系抗菌薬感受性予測における検討 感染症・リウマチ内科 筑波メディカルセンター病院 志智大介 鈴木広道 情報公開（15-11
Nanosphere, Inc. (Nasdaq: NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that six studies performed by various U.S. and international.. The concordance rate of the Verigene system (BC-GP, BC-GN) with conventional microbiological methods has been re-ported to be 92e98% for BC-GP [11e13,16,20e24] and 90e98% for BC-GN [14,25e27]. Most of the cases with. Blood cultures on admission detected Gram-positive rods, and a microarray-based, multiplexed, automated molecular diagnosis instrument (Verigene® system) identified Listeria spp. Although Listeria monocytogenes is rar
You can read all about the benefits of ESCMID membership and sign up online. Find out about ESCMID's organizational structure, its governing regulations as well as collaborations with other organizations. Find out more about. No category 全自動遺伝子解析装置を用い Verigene® 敗血症パネル 血液培養 検査 グラム 染色鏡検 分離培養 血液培養陽性 細菌と 薬剤耐性遺伝子検出 細菌同定 感受性結果 血流感染症の検査フロー [検 体] 患者血液 [培養時間] 1～5日 2.5時間 BC-GP 2時間 BC-GN Klebsiella pneumoniae, Klebsiella oxytoca, Proteus spp.) におけるVerigene BC-GN パネルにおいて耐性遺伝子検出について調査いたします。 参考所見として、2014年7月-2016年3月31日の介入試験期間において得られた、Verigen
Luminex verigene gram positive blood culture bc gp Verigene Gram Positive Blood Culture Bc Gp, supplied by Luminex, used in various techniques. Bioz Stars score: 88/100, based on 2 PubMed citations. ZERO BIAS - scores, articl This is the first manuscript published that describes the outcomes associated with clinically reported results from both Verigene blood culture tests Overall, Verigene BC-GN assay correctly identified 40/50 of all the gram-negative pathogens (3 Klebsiella pneumonia, 25 Escherichia coli, 5 Pseudomonas aeruginosa, 4 Acinetobacter spp, 1 Enterobacter spp, 2 Citrobacte
The Verigene Gram-negative blood culture (BC-GN) assay (Nanosphere, Inc., Northfield, IL) is a FDA-approved, random-access, automated, multiplexed nucleic acid test for the rapid ID of the most common GNB (and selected) Verigene BC-GN is a rapid in vitro diagnostic test that identifies a broad spectrum of gram-negative bacteria that cause bloodstream infections and determine resistance to commonly used antibiotics up to two to three days faste 3.BC-GN will not distinguish Escherichia coli from Shigella spp. Including S. dysenteriae, S. flexneri, S. boydii, and S. sonnei. 4. BC-GN will not detect OXA 51. 5. Serratia marcescens may yield a false negative result with BC-GN 6
Verigene BC-GN and BC-GP Panels 6-8 The Verigene (Luminex Corporation, Austin, TX, USA) system employs DNA microarray and nanoparticle technology for pathogen and genetic resistance marker identification. It utilizes two. View This Abstract Online Clinical Impact of Laboratory Implementation of Verigene BC-GN Microarray-Based Assay for Detection of Gram-Negative Bacteria in Positive Blood Cultures. J Clin Microbiol. 2016; 54(7):1789-1796 (ISSN: 1098-660X Nanosphere, Inc. (Nasdaq: NSPH) announced several business updates. The Company has: (1) received clearance from the U.S. Food and Drug Administration (FDA) for its Verigene Gram-Negative Blood.
Verigene(R) は、血流感染症の遺伝子検出検査において、製造販売承認を取得した最初の自動遺伝子解析装置となり、血液培養陽性が確認されてから. VERIGENE ® Gram-Negative Blood Culture Test (BC-GN) System Specifications System Specifications Electrical and Mechanical Specifications Reader Processor SP Rated Voltage AC 100V-200V AC 100V-200V 50-60 50-60. BC-GN did not identify 1 K. pneumoniae with a 98% (47/48) positive agreement. BC-GN does not include the detection of S. maltophilia (4), Serratia (4), Morganella (1), and B. fragilis (1) and these were excluded in the BC
VERIGENE BC-GN PERFORMANCE OVERVIEW Verigene BC-GN Performance vs. Reference Methods (n=1,412) Sensitivity (%) Specificity (%) Species Escherichia coli 99.8 99.4 Klebsiella pneumoniae 93.1 100 92.2 99. ventional identification and susceptibility testing. Prescription changes after Verigene identi-fication were more frequent in GP (17/41[41.5%]) than in GN (34/144[23.5%]). Among bacteremia due to single pathogen targeted b
医薬品（体外診断用医薬品を含む）, 施行年月日：2016/04/25 ～ 2016/05/01, ,承認番号,承認年月日,名称（販売名）,一般名. BC-GP Test Model: VERIGENE BC-GP Test Condition: New The VERIGENE BC-GP Test identifies genus, species, and genetic resistance determinants for a broad panel of gram-positive bacteria directly from positive blood cultur Nanosphere has obtained the CE-IVD Mark for its gram-negative blood culture test (BC-GN) on the automated sample-to-result Verigene system. The test expands Nanosphere's infectious disease test capabilities to include rapid detection of bacteria that can cause deadly bloodstream infections Verigene assay was performed, according to the Gram stain results. The Verigene BC-GP and BC-GN assays were performed according to the manufacture's package insert instructions, using 350 µL of blood culture media fro
SDS, Verigene Nucleic Acid Test Kit - BC-GN Extraction Tray, Greek (Greece) Downloads 18 Total Files 1 Create Date October 16, 2019 Last Updated October 16, 2019. 第28巻 第3号 目次 （2018年6月25日発行） 原著 ESBLs迅速検出法modified ESBL NDP testの有用性に関する検討 P173 上地 幸平. Among 144 patients with Verigene BC-GN target organisms, there was a moderate level of agreement between the reviewers regarding appropriateness of standard care antibiotics and a strong.
Luminex Corporationのプレスリリース（2017年6月6日 16時00分）Verigene 血液培養グラム陽性菌・薬剤耐性核酸テストとVerigene 血液培養グラム陰性菌・薬剤. グラム陰性桿菌菌血症に対するVerigene システム BC-GNパネルを用いた耐性遺伝子検出による第3世代セフェム系抗菌薬感受性予測における検討 グラム陰性桿菌菌血症（Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca又 NORTHBROOK, Ill., Sept. 22, 2015 -- Nanosphere, Inc. , a company enhancing medicine through targeted and flexible molecular diagnostics, announced that new clinical data for the Verigene®... | September 22, 201 Abstract: We evaluated the performance of the Verigene Gram-Negative Blood Culture Nucleic Acid Test (BC-GN; Nanosphere, Northbrook, IL, USA), an automated multiplex assay for rapid identification of positive blood cultures.
ルミネックス・コーポレーションのVerigene(R)血液培養グラム陽性菌・薬剤耐性核酸テストが保険適用を取得 AsiaNet 68791 ルミネックス. Performance Evaluation of the Verigene Gram-Positive and Gram-Negative Blood Culture Test for Direct Identification of Bacteria and Their Resistance Determinants from Positive Blood Cultures in Hong Kong PLOS ONE, Dec 201 The Verigene Gram-Positive Blood Culture (BC-GP) and Gram-Negative Blood Culture (BC-GN) nucleic acid tests (Nanosphere, Northbrook, IL, USA) are microarray. Verigene BC-GP and BC-GN identifiable targets 8/6/2015 Mokaddas E, MD, FRCPath 17 NB. Of the staphylococci only S.aures, S. epidermidis and S. lugdumesis can be identified as the other staphylococci are not present in. NORTHBROOK, Ill., May 14, 2014 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that six studies performed by various.
Luminex Corporation (NASDAQ: LMNX) 近日宣布，日本中央社会保险医疗理事会已批准日本厚生劳动省关于向两种VERIGENE®检查 （血培养革兰氏阳性菌(BC-GP) 检测和血培养革兰氏阴性菌(BC-GN) 检测）提供报销的建议 トップ ニュース 株式会社日立ハイテクノロジーズ、体外診断用医薬品として多項目同時遺伝子検査試薬を発売 株式会社日立ハイテクノロジーズ、体外診断用医薬品として多項目同時遺伝子検査試薬を発 【対象・方法】敗血症患者の血液培養陽性検体を対象に、Verigene・システムを用いたBC-GP検査またはBC-GN検査を行い、敗血症の起因菌及び薬剤耐性遺伝子を検出・同定する。比較対照として、従来の菌名同定・薬剤感受性検査 Last month, seven studies evaluating the performance & clinical impact of select Verigene® multiplex infectious disease tests were presented at ASM 2015 In this study, we evaluated the microarray-based Verigene Gram-negative blood culture (BC-GN) assay in the identification of 8 genus or species targets and 6 genetic resistance determinants in positive blood culture broths. A tota
